Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 236 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine-naloxone Clear all
Completed Phase 4 Interventional Results available

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

NCT02038790
View directory record Official record
Conditions
Opioid Dependence
Interventions
Suboxone Sublingual Film, Zubsolv sublingual tablets
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients

NCT00879996
View directory record Official record
Conditions
Opiate Addiction
Interventions
Methadone, Buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 13, 2026, 6:07 PM EDT
Completed No phase listed Observational

Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions

NCT04049799
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
Interventions
Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

NCT01999114
View directory record Official record
Conditions
ECG Effects
Interventions
Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Treatment for Opioid Dependence

NCT02187198
View directory record Official record
Conditions
Opioid Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 13, 2026, 6:07 PM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

NCT03911739
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Naltrexone-P1 A-Cocaine

NCT00733720
View directory record Official record
Conditions
Cocaine-related Disorders
Interventions
Suboxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Terminated Phase 3 Interventional

Study of Probuphine in Patients With Opioid Dependence

NCT00772785
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 1 Interventional

Buprenorphine and Naloxone Combination Study - 10

NCT00015288
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

NCT01260675
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine HCl/Naloxone HCl
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

NCT01848054
View directory record Official record
Conditions
Opioid-Related Disorders, Opiate Dependence
Interventions
Buprenorphine/naloxone sublingual tablets, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

NCT00000344
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

NCT03616236
View directory record Official record
Conditions
Opioid Use
Interventions
Buprenorphine/Naloxone, Treatment as usual
Drug · Other
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 13, 2026, 6:07 PM EDT
Not yet recruiting Phase 4 Interventional

Examining Analgesic Synergy and Efficacy in Trauma Care

NCT07435077
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine, Oxycodone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Not applicable Interventional Results available

HEALing Communities Study

NCT04111939
View directory record Official record
Conditions
Opioid Use Disorder (OUD)
Interventions
Communities That HEAL, Wait-list control
Other
Lead sponsor
RTI International
Other
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Lexington, Kentucky • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Results available

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

NCT01637922
View directory record Official record
Conditions
Hepatitis C
Interventions
BI 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Atlanta, Georgia • Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 13, 2026, 6:07 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

NCT06087991
View directory record Official record
Conditions
Opioid Abuse
Interventions
Implementation of the BINDeR-Tx service model
Behavioral
Lead sponsor
Jerry Cochran
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 13, 2026, 6:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

NCT00880841
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine / Naloxone
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 4 Interventional Results available

Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

NCT01903005
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
Higher bioavailability BNX sublingual tablets
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Jefferson County, Alabama • Marion County, Alabama • Winston County, Alabama + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 13, 2026, 6:07 PM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

NCT00000330
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Opioid-Related Disorders
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 13, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

INDV-6001 Multiple-Dose Pharmacokinetic Study

NCT06576843
View directory record Official record
Conditions
Moderate to Severe Opioid Use Disorder
Interventions
INDV-6001, Suboxone, Sublocade
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Diego, California • Miami Lakes, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 13, 2026, 6:07 PM EDT
Not listed Not applicable Interventional

Improving Office Based Treatment of Opioid Use Disorder With Technology

NCT03586466
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
BupreCare, Buprenorphine/naloxone, MEMS
Device · Drug · Other
Lead sponsor
MedicaSafe, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 13, 2026, 6:07 PM EDT